Haleon PLC

Major Shareholding Notification • Jan 17, 2025

National Storage Mechanism | Additional information

RNS Number : 8362T

Haleon PLC

17 January 2025

17 January 2025   

HALEON PLC  

​ ("Haleon" or "the Company")   

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

HALEON PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Pfizer Inc.

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

4. Details of the shareholder

Name	City of registered office	Country of registered office
State Street Nominees Limited	London	United Kingdom
Guaranty Nominees Limited	London	United Kingdom

5. Date on which the threshold was crossed or reached

17-Jan-2025

6. Date on which Issuer notified

17-Jan-2025

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	7.310000	0.000000	7.310000	661709764
Position of previous notification (if applicable)	15.040000	0.000000	15.040000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
Ordinary Shares GB00BMX86B70		267251860		2.950000
Restricted ADSs		394457904		4.360000
Sub Total 8.A	661709764		7.310000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

This notification relates to the sale by Pfizer Inc. ("Pfizer") of a portion of its interest in Haleon plc ("Haleon").

Pfizer sold 700,000,000 Haleon ordinary shares pursuant to a secondary offering announced on 14 January 2025.

These calculations are based on Haleon's issued voting share capital of 9,053,360,882 ordinary shares with voting rights, as communicated by Haleon in their announcement on total voting rights and capital dated 1 November 2024.

Pfizer holds its ordinary shares in Haleon through (i) State Street Nominees Limited, and (ii) Guaranty Nominees Limited (in respect of its American depositary shares representing ordinary shares), which hold the legal title to those shares on Pfizer's behalf.

12. Date of Completion

17-Jan-2025

13. Place Of Completion

New York, USA

Amanda Mellor, Company Secretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLUBANRVKUAAAR